Your browser doesn't support javascript.
loading
CAR T-Cell Therapy: Update on the State of the Science.
Lamprecht, Misty; Dansereau, Colleen.
Afiliação
  • Lamprecht M; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
  • Dansereau C; Dana-Farber/Boston Children's Cancer and Blood Disorders Center.
Clin J Oncol Nurs ; 23(2): 6-12, 2019 04 01.
Article em En | MEDLINE | ID: mdl-30880819
BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy leverages the power of the patient's own immune system by serving as a bridge to connect genetically modified T cells to the surface antigens of tumor cells based on targeted ligands. Clinical trials have demonstrated compelling overall response and survival rates in individuals with B-cell malignancies. The current approved agents target CD19, an antigen commonly overexpressed in B-cell hematologic and other malignancies. OBJECTIVES: This article provides information on the current state of the science related to commercially available CAR T-cell products and examines how CAR T-cell science is evolving. METHODS: An overview of pathophysiology, indications, and nursing implications of the currently approved CAR T-cell agents is presented. Future directions for CAR T-cell development and treatment indications are discussed. FINDINGS: Tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) received approval in 2017 for the treatment of B-cell precursor acute lymphoblastic leukemia in pediatric and young adult patients, and relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in adult patients, respectively. Additional indications have since been approved, and new agents are in development.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T / Imunoterapia Adotiva Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T / Imunoterapia Adotiva Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article